We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    DNA Evaluation of Fragments for Early Interception – Lung Cancer Training Study
Previous Study | Return to List | Next Study

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study) (DELFI-L101)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04825834
Recruitment Status : Recruiting
First Posted : April 1, 2021
Last Update Posted : November 29, 2022
Sponsor:
Information provided by (Responsible Party):
Delfi Diagnostics Inc.

Brief Summary:
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.

Condition or disease Intervention/treatment
Lung Cancer Head and Neck Cancer Esophageal Cancer Bladder Cancer Kidney Cancer Stomach Cancer Colorectal Cancer Pancreas Cancer Liver Cancer Other: Blood Sample Collection

Detailed Description:
Subjects will be enrolled into the DELFI-L101 study after informed consent and eligibility is confirmed. At enrollment, subjects will have blood specimens collected (~40 mL) and 12 months post-enrollment their medical records will be reviewed.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2500 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
Actual Study Start Date : March 22, 2021
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : March 31, 2024


Group/Cohort Intervention/treatment
Individuals eligible for Lung Cancer screening with Lung Cancer diagnosis Other: Blood Sample Collection
Subjects enrolled in the DELFI-L101 will have blood specimens collected (~40 mL) at enrollment.

Individuals eligible for Lung Cancer screening with no cancer diagnosis Other: Blood Sample Collection
Subjects enrolled in the DELFI-L101 will have blood specimens collected (~40 mL) at enrollment.

Individuals eligible for Lung Cancer screening with Non-Lung Cancer diagnosis Other: Blood Sample Collection
Subjects enrolled in the DELFI-L101 will have blood specimens collected (~40 mL) at enrollment.




Primary Outcome Measures :
  1. Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC. [ Time Frame: Approximately 12 months ]

Secondary Outcome Measures :
  1. Accuracy (sensitivity and specificity) in clinical subgroups of interest [ Time Frame: Approximately 12 months ]
  2. Accuracy of tumor of origin (confusion matrix of predicted versus actual cancer type) [ Time Frame: Approximately 12 months ]
  3. Adverse events (AEs) associated with the blood specimen collection [ Time Frame: Point in time of blood specimen collection (1day) at enrollment ]
  4. Expected distribution of the DELFI score in the intended use population [ Time Frame: Approximately 12 months ]
  5. Analytical performance (e.g. repeatability/reproducibility) [ Time Frame: Approximately 12 months ]
  6. Accuracy of multi-cancer detection measured by sensitivity, specificity, and the AUC of the ROC and tissue of origin (TOO) accuracy [ Time Frame: Approximately 12 months ]

Biospecimen Retention:   Samples With DNA
Residual blood specimens may be used to develop and evaluate performance of biomarker assays to detect cancers or other conditions, laboratory process improvements, and proficiency testing. Residual blood specimens will be de-identified and will be stored for no more than 20 years.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals ≥ 50 years of age who are eligible for lung cancer screening from medical, surgical, sub- specialty clinics, lung cancer screening, lung nodule, thoracic surgery, and chest clinic practices.
Criteria

Inclusion Criteria:

All Subjects:

  1. Ability to understand and provide written informed consent
  2. Age ≥ 50 years
  3. Current or Former Smoker
  4. ≥ 20 pack-years (pack years = number of packs per day X number of years smoked)

    Inclusion Group 1: High Risk Patients that meet criteria 5 and 6 below:

  5. Prior thoracic imaging (computed tomography (CT)) within 12 months of enrollment OR Planned thoracic imaging (CT) as part of standard of care within 6 weeks of enrollment

    AND

  6. Meet one of the criteria below:

    1. No suspected or confirmed lung cancer diagnosis OR
    2. Suspected of lung cancer OR
    3. Confirmed, untreated lung cancer

    Inclusion Group 2: High Risk Patients that meet the following criteria:

  7. Pathologic confirmed, invasive non-lung cancer diagnosis, originating from the esophagus (upper), colon or rectum, pancreas, stomach (including lower esophagus), head and neck, bladder, kidney, or liver, with no prior systemic therapy, definitive therapy, radiation, or surgical resection. OR Clinically confirmed invasive non-lung cancer diagnosis originating from the pancreas, kidney, or liver, based on imaging and clinical judgement with planned treatment and no prior systemic therapy, definitive therapy, radiation, or surgical resection.

Exclusion Criteria:

All Subjects:

  1. Prior systemic therapy, definitive therapy, radiation, or surgical resection for cancer within one year prior to enrollment (with the exception of organ biopsies or surgery for non-melanoma skin cancer)
  2. Any history of hematologic malignancies or myelodysplasia
  3. Any history of organ tissue transplantation
  4. Any history of blood product transfusion
  5. Current pregnancy
  6. Any condition that in the opinion of the Investigator should preclude the subject's participation in the study
  7. Prior systemic therapy, definitive therapy, radiation, or surgical resection for the enrollment cancer diagnosis (with the exception of organ biopsies or surgery for non-melanoma skin cancer are not exclusionary)
  8. Enrollment in the DELFI-L201 study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04825834


Contacts
Layout table for location contacts
Contact: Ashley Birch (917) 781-3727 clindev@delfidiagnostics.com

Locations
Layout table for location information
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Luke RG Pike, MD, DPhil         
United States, Ohio
The Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Peter Mazzone, MD         
Sponsors and Collaborators
Delfi Diagnostics Inc.
Investigators
Layout table for investigator information
Principal Investigator: Peter Mazzone, MD, MPH The Cleveland Clinic
Principal Investigator: Luke RG Pike, MD, DPhil Memorial Sloan Kettering Cancer Center
Layout table for additonal information
Responsible Party: Delfi Diagnostics Inc.
ClinicalTrials.gov Identifier: NCT04825834    
Other Study ID Numbers: DELFI-L101 Study
First Posted: April 1, 2021    Key Record Dates
Last Update Posted: November 29, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Individual participant data that underline the results reported in publications of the study may be shared after de-identification. This may include text, tables, figures, and appendices. The study protocol, statistical analysis plan, and informed consent form will also be shared. Data may be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Kidney Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Endocrine Gland Neoplasms
Respiratory Tract Diseases
Digestive System Diseases
Gastrointestinal Diseases
Urologic Diseases
Kidney Diseases
Pancreatic Diseases
Endocrine System Diseases
Stomach Diseases